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Lymphoproliferative diseaseAbstract In post-transplant patients, de novo malignancies such as post-transplant lymphoprolifera-
tive disease (PTLD), lung carcinoma, renal cell carcinoma, cutaneous malignancies, and Kaposi sar-
coma are now seen. The immunotherapy used to prevent graft failure indirectly increases their risk.
We present a rare case of visceral Kaposi sarcoma in a patient with orthotopic liver transplant.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
De novo malignancy is now seen to have a rising trend after
solid organ transplant. The incidence of de novo malignancy
is said to range from 2.3% to 26% (1,2). Various de novo
malignancies are seen after liver transplant. Most common
of them is cutaneous malignancies as said in western literature,
followed by post-transplant lymphoproliferative disease
(PTLD) (1). Other visceral organ malignancies include lung
cancer, renal cell carcinoma, and hepatocellular carcinoma.
Visceral Kaposi sarcoma is a rare de novo malignancy seenin postliver transplant patients. We report a rare case of vis-
ceral Kaposi sarcoma seen in an Asian male after orthotopic
liver transplantation.
2. Case report
A 35 year old male fromMongolia suffering from HCV related
chronic liver disease (CLD) was referred to our institute for
liver transplantation. Preoperative CT was consistent with
CLD. Orthotopic right lobe liver transplant from a living
donor was performed. The post-operative period was unevent-
ful and patient was discharged from the hospital. He was given
tacrolimus, mycophenolate mofetil and prednisolone as
immunosuppressants. The patient was asymptomatic for
6 months postoperatively till he presented to a local hospital
in Mongolia with jaundice and increased total bilirubin and
alkaline phosphatase. The patient was referred back to our
336 S. Gupta et al.institution. Triphasic CT revealed irregular hypodense lesions
in relation to segment 8 of the grafted liver and also along
its inferior and posterior margins. Irregular hypodense soft tis-
sue was noted in periportal region extending along periportal
planes into the liver parenchyma, thereby causing mild intra-
hepatic biliary radical dilatation. All of these lesions showed
signiﬁcant peripheral arterial phase enhancement with wash-
out on delayed phase. In addition to these lesions, multiple het-
erogeneously enhancing enlarged lymph nodes were seen in
periportal and peripancreatic, gastro hepatic space and along
pre and para-aortic regions (Fig. 1).
Ultrasound guided biopsy was performed, which was
reported as spindle cell sarcoma. In view of history of immuno-
suppression, immunohistochemistry markers for Kaposi sar-
coma were evaluated. CD 34 and CD 31 markers came out
to be positive, and the diagnosis of Kaposi’s sarcoma was
made (Fig. 2).
Patient was admitted and immunotherapy was changed to
sirolimus and ganciclovir. Follow-up imaging with MRIFig. 1 CT triple phase liver angiography images on plain (A and D),
lesions at periportal region, showing arterial phase enhancement and w
intraparenchymal lesions (arrow head) seen traversing along the porta
Fig. 2 Histopathology slides in HE (A) showing spindle cells. Immunorevealed multiple well deﬁned T2 hyper intense lesions in the
liver along with extensive soft tissue at the porta, peripancre-
atic and pre aortic area (Fig. 3). These lesions did not restrict
on diffusion weighted image. MRCP revealed intrahepatic bil-
iary radical dilatation for which percutaneous trans-hepatic
biliary drainage was performed. However patient deteriorated,
developed multiorgan failure and ultimately died.3. Discussion
The risk of de novo malignancies is said to be increased by
200–500 times after solid organ transplantation (3). The type
of malignancy varies with the type of immunosuppressants
used. For example, tacrolimus is said to increase the risk of
haematological malignancies and cyclosporine increases the
risk of skin cancers.
Kaposi sarcoma (KS) is a low grade vascular tumor and in
60% of cases, it presents as skin and mucosal lesions. In 40%arterial (B and E) and portal (C and F) phases, multiple hypodense
ashout on portal images (black arrow). Multiple arterial enhancing
l vessels and also in subcapsular location (white arrow).
histochemistry marker slides, positive for CD 31 (B) and CD 34 (C).
Fig. 3 Magnetic resonance imaging in T2 weighted sequence in axial (A and B), coronal (C) showing hyperintense lesions seen along
portal radicals (green arrows) and soft tissue nodules in periportal and retroperitoneum (yellow arrows). Note is made of ascites and
pleural effusion (*). 3D T2 space MIP image (D) showing intrahepatic biliary radical dilatation with hilar block.
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lungs, lymph nodes, etc. is seen (4). It is classically described
as four variants: Classic KS, endemic (African) KS, iatrogenic
(organ transplant-related) KS, or acquired immunodeﬁciency
syndrome (AIDS)-related KS (5).
The Cincinnati Transplant Tumor Registry (CTTR)
reported that Kaposi sarcoma accounted for 5–7% of all
malignancies in transplant recipients (4). KS is commonly seen
in postliver transplant patients, followed by heart and kidney
transplantation which is most likely due to increased incidence
of associated HHV-8 infection (6).
The radiological ﬁndings in visceral Kaposi sarcoma are
varied and depend upon the organ of involvement. In postliver
transplant patients, ultrasound may show multiple inhomoge-
neous hyperechoic periportal bands and nodules (7).
CT ﬁndings include numerous small liver nodules in the
periportal and subcapsular area causing widening of porta
(7). Nodular lesions may be seen in the mesentery and retro
peritoneum. These nodules are classically described to have
delayed enhancement and become more conspicuous on
delayed sequences. In contrast to this, in our case these nodules
showed arterial phase enhancement and appeared hypoatten-
uating on delayed images.
Magnetic resonance imaging of Kaposi sarcoma of liver
shows similar subcapsular nodules as seen on CT, which
appear hyperintense on T2 weighted images. These lesions
can show diffusion restrictions are usually hyperintense on
inphase, hypointense on opposed phase images indicating the
presence of fat within these lesions (8). In our case it did not
show restricted diffusion as well as nothing was seen on
opposed phase images.
The major imaging differential diagnosis is PTLD, but as
contrast to KS, PTLD does not enhance in arterial phaseand the lesions are better deﬁned and nodular on appearance
(9). However both PTLD and KS pose as diagnostic dilemma
when it comes to imaging. Histopathological conﬁrmation is
always required in these cases. Where KS shows spindle cells
with sarcomatous changes, immunohistochemistry is required
for ﬁnal characterization using CD 34, CD 32 and marker
for HHV 8 virus. PTLD on histopathology appears same as
lymphoma.
Another imaging differential that should be considered is of
de novo hepatocellular carcinoma. On imaging it shows char-
acteristic arterial phase enhancement with washout in venous
phase and delayed capsular enhancement. De novo HCC is
rarely encountered and chronic HCV and HBV infection
remains a high risk factor for the development of HCC (10).
No deﬁnite treatment regime has been deﬁned for post-
transplant KS. Therapeutic choice ranges from surgical
excision, radiation therapy, intralesional injection of chemo-
therapeutic agents, reduction of immunosuppressive therapy
to systemic chemotherapy (11). The most effective approach
is reduction or cessation of immunosuppressive therapy as it
is said to be a consequence of prolonged immunosuppression.
A multi-disciplinary approach is required to diagnose and
treat post-transplant KS. On imaging KS might be difﬁcult
to diagnose but it should always kept in the list of differential
when inﬁltrative visceral lesions are seen in postliver transplant
patients. Optimization of immunotherapy should be the main
treatment. Screening for HHV-8 is also said to be useful as
primary prevention.Conﬂict of interest
None declared.
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